Companies · Healthtech

Upperline Health, Inc.

NASHVILLE · Healthtech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Upperline Health, Inc. — recommendation, valuation, rhythm, risks.
$43.8M
Total raised · real
2
Rounds
1.4×
Latest step-up
Top 12%
Sector rank · raised
Series B
Latest stage · inferred · Wed Feb 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Upperline Health, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.78× the median modeled value of Series B Healthtech companies in 2019–2021 (56 peers) — value vs value, same stage and era.
  • Within the normal band (78% of peer median) for its niche.
Dormant
  • Last raise 6.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Healthtech

Upperline Health, Inc. is one of 2138 Healthtech companies tracked from NASHVILLE. By capital raised it ranks in the upper tier (ahead of 89% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2016
Year incorporated
2020-02-05
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2018-04-06 Raised $30M (real) Modeled valuation $737M (est)$30M$737MSeries B2018Series A · 2020-02-05 Raised $10M (real) Modeled valuation $226M (est)$10M$226MSeries A2020Series B · 2020-02-05 Raised $14M (real) Modeled valuation $348M (est)$14M$348MSeries B2020+$10M+$14MCumulative $54M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$29.8M · 2018
Bridge · Series B-stage$10.0M · 2020smaller follow-on
Series B extension$14.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$347.7M
Base estimate est.
$33.0M
Conservative case
$1.3B
Upside case
$77.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Series B · modeled $737.3M · 2018-04-062018Series A · modeled $226.4M · 2020-02-05Series B · modeled $347.7M · 2020-02-052020
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.38×/yr
Annual markup
1.67×/yr upside case
6.0 yr
Elapsed time used
6.4 yr actual, capped for stale marks
healthtech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$23.9M/yr
Capital velocity
8.2 yr
On record since
2018
First round
3
Rounds on file
How it compares to the market

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 9.8× above median
This company$43.8M
Sector median$4.5M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.8× of median
This company$14.0M
Sector median$18.3M
Modeled value — vs sector median (estimate, all stages) 10× above median
This company$347.7M
Sector median$33.8M

Raised more than 89% of sector peers (real $). Modeled value above 91% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #44 of 56.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Solera Health, Inc. · Series B Raised $79.1M · modeled $935.6M (est)Icebreaker Health, Inc. · Series B Raised $51.5M · modeled $890.1M (est)Buoy Health, Inc. · Series B Raised $66.7M · modeled $837.4M (est)Stroma Medical Corp · Series B Raised $43.0M · modeled $767.6M (est)HealthJoy, Inc. · Series B Raised $45.5M · modeled $743.5M (est)Appriss Health Holdings, Inc. · Series B Raised $38.1M · modeled $718.0M (est)Superconductive Health, Inc. · Series B Raised $61.0M · modeled $717.0M (est)Wheel Health, Inc. · Series B Raised $36.7M · modeled $686.1M (est)Mindoula Health, Inc. · Series B Raised $30.7M · modeled $663.2M (est)Flowonix Medical Inc · Series B Raised $104.6M · modeled $656.8M (est)Sirona Medical, Inc. · Series B Raised $53.0M · modeled $638.3M (est)HealthPlan One Holdings, Inc. · Series B Raised $28.6M · modeled $621.6M (est)Upperline Health, Inc. (this company) Raised $43.8M · modeled $347.7M (est)Upperline Health, Inc.
CompanyStageRaised · realValue · estvs peer med.
Solera Health, Inc.Series B$79.1M$935.6M2.09×
Icebreaker Health, Inc.Series B$51.5M$890.1M1.99×
Buoy Health, Inc.Series B$66.7M$837.4M1.87×
Stroma Medical CorpSeries B$43.0M$767.6M1.72×
HealthJoy, Inc.Series B$45.5M$743.5M1.66×
Appriss Health Holdings, Inc.Series B$38.1M$718.0M1.61×
Superconductive Health, Inc.Series B$61.0M$717.0M1.60×
Wheel Health, Inc.Series B$36.7M$686.1M1.53×
Mindoula Health, Inc.Series B$30.7M$663.2M1.48×
Flowonix Medical IncSeries B$104.6M$656.8M1.47×
Sirona Medical, Inc.Series B$53.0M$638.3M1.43×
HealthPlan One Holdings, Inc.Series B$28.6M$621.6M1.39×
Upperline Health, Inc. this companySeries B$43.8M$347.7M0.78×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$29.8M2018-04-06$165.3M$737.3M90%
Series A$10.0M2020-02-05$45.6M$226.4M90%
Series B$14.0M2020-02-05$77.9M$347.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$29.8M2018-04-06
    • First recorded raise — entered as Series B.
    • 7 investors on this round.
  2. Series A$10.0M2020-02-05
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  3. Series B$14.0M2020-02-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
    • 6 investors on this round.
Intelligence
2021 ~Q1
Modeled next raise · ~11mo cadence
$19.6M
Modeled next size est.range $14.0M$31.4M
1.4×
Last step-up
$23.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jeff Crisan3 other2018-04
Darin Gordon2 other2020-02
Charlie Morgan1 other2020-02
David Thorpe1 other2018-04
Mike Lester1 other2018-04
Stephen Nash2018-04
Registry & provenance

Upperline Health, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1737725
SEC CIK
2016
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Upperline Health Holdings, Inc.HealthtechSeries B$47.5M$67.8Mnetwork5 shared operators · same sector · same stage
Recuro Health, Inc.HealthtechSeries B$44.2M$340.0Msame sector · same stage
Atropos Health IncHealthtechSeries B$44.3M$232.5Msame sector · same stage
OtoNexus Medical Technologies, Inc.HealthtechSeries B$44.5M$151.7Msame sector · same stage
FirstHand Health, Inc.HealthtechSeries B$42.9M$302.8Msame sector · same stage
Bradford Health Partners, LLCHealthtechSeries B$44.8M$111.5Msame sector · same stage
XII Medical, Inc.HealthtechSeries B$45.1M$146.1Msame sector · same stage
Meru Health Holding Inc.HealthtechSeries B$42.4M$452.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Upperline Health Holdings, Inc.HealthtechSeries B$67.8M97%
Line Health, Inc.HealthtechPre-Seed$25.1M87%
Streamline Health Solutions Inc.HealthtechSeries A$217.5M87%
Mae Health, Inc.HealthtechSeed$7.6M86%
Scottline Healthcare Solutions, Inc.HealthtechSeries A$270.9M86%
Level Health, Inc.HealthtechSeed$29.2M85%
Highline Wellness Inc.HealthtechSeed$61.8M85%
Axena Health, Inc.HealthtechSeries B$288.0M84%
Frequently asked
How much funding has Upperline Health, Inc. raised?
Upperline Health, Inc. has raised approximately $43.8M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Upperline Health, Inc.'s estimated valuation?
Provath's modeled valuation for Upperline Health, Inc. is approximately $347.7M (modeled range $33.0M–$1.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Upperline Health, Inc. at?
Upperline Health, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Wed Feb 05.
What does Upperline Health, Inc. do and where is it based?
Upperline Health, Inc. operates in the Healthtech sector, based in NASHVILLE.
Explore related

See where Upperline Health, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Upperline Health, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.